Oncology

CHICAGO | Truly groundbreaking change in the first-line treatment of metastatic melanoma has arrived for patients relegated to using the same largely ineffective regimens for many years.

CHICAGO | The aromatase inhibitor exemestane reduces the risk of invasive breast cancer by 65% in high-risk postmenopausal women, according to a large phase III, placebo-controlled trial led and coordinated by Canada’s NCIC Clinical Trials Group.